French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)

Y. Neuzillet; B. Pradère; E. Xylinas; Y. Allory; F. Audenet; Y. Loriot; A. Masson-Lecomte; M. Roumiguié; T. Seisen; O. Traxer; P. Leon; M. Roupret

doi:10.1016/j.purol.2022.08.006

French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)

Titre traduit de la contribution: Recommandations du comité de cancérologie de l'Association Française d'Urologie - actualisation 2022-2024: tumeurs de la vessie n'infiltrant pas le muscle (TVNIM)

Y. Neuzillet, B. Pradère, E. Xylinas, Y. Allory, F. Audenet, Y. Loriot, A. Masson-Lecomte, M. Roumiguié, T. Seisen, O. Traxer, P. Leon, M. Roupret

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

11 Citations (Scopus)

Résumé

Objective: To update the ccAFU recommendations for the management of bladder tumours that do not infiltrate the bladder muscle (NBMIC). Methods: A systematic review (Medline) of the literature from 2020 to 2022 was performed, taking account of the diagnosis, treatment options and surveillance of NMIBC, while evaluating the references with their levels of evidence. Results: The diagnosis of NMIBC (Ta, T1, CIS) is made after complete full-thickness tumour resection. The use of bladder fluorescence and the indication of a second look (4–6 weeks) help to improve the initial diagnosis. The EORTC score is used to assess the risk of recurrence and/or tumour progression. Through the stratification of patients in low, intermediate and high-risk categories, adjuvant treatment can be proposed: intravesical chemotherapy (immediate postoperative, initiation regimen) or BCG (initiation and maintenance regimen) instillations, or even the indication of cystectomy for BCG-resistant patients. Conclusion: Updating the ccAFU recommendations should contribute to improving patient management, as well as the diagnosis and treatment of NMIBC.

Titre traduit de la contribution	Recommandations du comité de cancérologie de l'Association Française d'Urologie - actualisation 2022-2024: tumeurs de la vessie n'infiltrant pas le muscle (TVNIM)
langue originale	Anglais
Pages (de - à)	1102-1140
Nombre de pages	39
journal	Progres en Urologie
Volume	32
Numéro de publication	15
Les DOIs	https://doi.org/10.1016/j.purol.2022.08.006
état	Publié - 1 nov. 2022

Accès au document

10.1016/j.purol.2022.08.006

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{de64f0e390ec4e08bc3437f9d01371fb,

title = "French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)",

abstract = "Objective: To update the ccAFU recommendations for the management of bladder tumours that do not infiltrate the bladder muscle (NBMIC). Methods: A systematic review (Medline) of the literature from 2020 to 2022 was performed, taking account of the diagnosis, treatment options and surveillance of NMIBC, while evaluating the references with their levels of evidence. Results: The diagnosis of NMIBC (Ta, T1, CIS) is made after complete full-thickness tumour resection. The use of bladder fluorescence and the indication of a second look (4–6 weeks) help to improve the initial diagnosis. The EORTC score is used to assess the risk of recurrence and/or tumour progression. Through the stratification of patients in low, intermediate and high-risk categories, adjuvant treatment can be proposed: intravesical chemotherapy (immediate postoperative, initiation regimen) or BCG (initiation and maintenance regimen) instillations, or even the indication of cystectomy for BCG-resistant patients. Conclusion: Updating the ccAFU recommendations should contribute to improving patient management, as well as the diagnosis and treatment of NMIBC.",

keywords = "BCG, Bladder, Bladder tumours, Cancer, Cystectomy, Survival, Urine cytology, Urothelial carcinoma",

author = "Y. Neuzillet and B. Prad{\`e}re and E. Xylinas and Y. Allory and F. Audenet and Y. Loriot and A. Masson-Lecomte and M. Roumigui{\'e} and T. Seisen and O. Traxer and P. Leon and M. Roupret",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Masson SAS",

year = "2022",

month = nov,

day = "1",

doi = "10.1016/j.purol.2022.08.006",

language = "English",

volume = "32",

pages = "1102--1140",

journal = "Progres en Urologie",

issn = "1166-7087",

number = "15",

}

TY - JOUR

T1 - French AFU Cancer Committee Guidelines - Update 2022-2024

T2 - Non-muscle-invasive bladder cancer (NMIBC)

AU - Neuzillet, Y.

AU - Pradère, B.

AU - Xylinas, E.

AU - Allory, Y.

AU - Audenet, F.

AU - Loriot, Y.

AU - Masson-Lecomte, A.

AU - Roumiguié, M.

AU - Seisen, T.

AU - Traxer, O.

AU - Leon, P.

AU - Roupret, M.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - Objective: To update the ccAFU recommendations for the management of bladder tumours that do not infiltrate the bladder muscle (NBMIC). Methods: A systematic review (Medline) of the literature from 2020 to 2022 was performed, taking account of the diagnosis, treatment options and surveillance of NMIBC, while evaluating the references with their levels of evidence. Results: The diagnosis of NMIBC (Ta, T1, CIS) is made after complete full-thickness tumour resection. The use of bladder fluorescence and the indication of a second look (4–6 weeks) help to improve the initial diagnosis. The EORTC score is used to assess the risk of recurrence and/or tumour progression. Through the stratification of patients in low, intermediate and high-risk categories, adjuvant treatment can be proposed: intravesical chemotherapy (immediate postoperative, initiation regimen) or BCG (initiation and maintenance regimen) instillations, or even the indication of cystectomy for BCG-resistant patients. Conclusion: Updating the ccAFU recommendations should contribute to improving patient management, as well as the diagnosis and treatment of NMIBC.

AB - Objective: To update the ccAFU recommendations for the management of bladder tumours that do not infiltrate the bladder muscle (NBMIC). Methods: A systematic review (Medline) of the literature from 2020 to 2022 was performed, taking account of the diagnosis, treatment options and surveillance of NMIBC, while evaluating the references with their levels of evidence. Results: The diagnosis of NMIBC (Ta, T1, CIS) is made after complete full-thickness tumour resection. The use of bladder fluorescence and the indication of a second look (4–6 weeks) help to improve the initial diagnosis. The EORTC score is used to assess the risk of recurrence and/or tumour progression. Through the stratification of patients in low, intermediate and high-risk categories, adjuvant treatment can be proposed: intravesical chemotherapy (immediate postoperative, initiation regimen) or BCG (initiation and maintenance regimen) instillations, or even the indication of cystectomy for BCG-resistant patients. Conclusion: Updating the ccAFU recommendations should contribute to improving patient management, as well as the diagnosis and treatment of NMIBC.

KW - BCG

KW - Bladder

KW - Bladder tumours

KW - Cancer

KW - Cystectomy

KW - Survival

KW - Urine cytology

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85142402916&partnerID=8YFLogxK

U2 - 10.1016/j.purol.2022.08.006

DO - 10.1016/j.purol.2022.08.006

M3 - Article

C2 - 36400479

AN - SCOPUS:85142402916

SN - 1166-7087

VL - 32

SP - 1102

EP - 1140

JO - Progres en Urologie

JF - Progres en Urologie

IS - 15

ER -